| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Apellis Pharmaceuticals, Inc.
13D/A
Amendment 1
APLS · 03753U106
|
0% |
5/14/2026
Event 5/14/2026
|
|||
|
Apellis Pharmaceuticals, Inc.
13D
APLS · 03753U106
|
14.2% |
4/6/2026
Event 3/31/2026
|
|||
|
Sage Therapeutics, Inc.
13D/A
Amendment 2
SAGE · 78667J108
|
0% |
7/30/2025
Event 7/30/2025
|
|||
| Biogen Inc. | 0% | ||||
| Biogen MA Inc. | 0% | ||||
|
Sage Therapeutics, Inc.
13D/A
Amendment 1
SAGE · 78667J108
|
10.0% |
7/21/2025
Event 7/21/2025
|
|||
| Biogen Inc. | 10.0% | ||||
| Biogen MA Inc. | 10.0% | ||||
|
Sage Therapeutics, Inc.
13D
SAGE · 78667J108
|
10.2% |
1/10/2025
Event 1/10/2025
|
|||
| Biogen Inc. | 10.2% | ||||
| Biogen MA Inc. | 10.2% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.